| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| Other Sizes |
| Targets |
(R)-Monepantel does not have a defined molecular target for its reported anticancer activity, and it is considered inactive as a nematicide. Its lack of nematicidal effect suggests it does not effectively interact with the parasite-specific targets of the parent compound. The mechanism underlying its potential anticancer properties remains to be elucidated.
|
|---|---|
| ln Vitro |
Specific in vitro activity data for (R)-Monepantel are not detailed in the available literature. However, it is noted to have potential anticancer activity. In contrast, it shows no nematicidal activity, confirming that the R-enantiomer is the inactive form against parasitic nematodes.
|
| ln Vivo |
Specific in vivo activity data for (R)-Monepantel are not provided in the available sources. Its reported potential anticancer activity would need to be validated in appropriate in vivo models. However, it is confirmed to have no nematicidal effect in vivo.
|
| Enzyme Assay |
Non-cellular enzyme/receptor binding assays for (R)-Monepantel are not detailed in the provided literature. For similar compounds, such assays would typically involve assessing binding affinity to target proteins or enzymes to understand the molecular basis of its activity or lack thereof.
|
| Cell Assay |
In vitro cellular assays for (R)-Monepantel are not specified in the available sources. Given its reported potential anticancer activity, such assays would likely involve testing its effects on cancer cell lines to evaluate proliferation inhibition, apoptosis induction, or other anti-cancer mechanisms.
|
| Animal Protocol |
In vivo animal experiments for (R)-Monepantel are not described. For anthelmintic compounds, efficacy is typically tested in animal models of parasitic infection. However, since (R)-Monepantel lacks nematicidal activity, such studies would not show efficacy. Its anticancer potential would require testing in tumor-bearing animal models.
|
| ADME/Pharmacokinetics |
Pharmacokinetic (PK) properties for (R)-Monepantel are not detailed in the available literature. As the R-enantiomer of Monepantel, its PK profile would likely differ from the racemic mixture or the S-enantiomer, potentially affecting its absorption, distribution, metabolism, and excretion.
|
| Toxicity/Toxicokinetics |
Toxicological data for (R)-Monepantel are not provided in the available sources. As a research compound, its safety profile has not been extensively characterized. It is intended for research use only and not for human consumption.
|
| References | |
| Additional Infomation |
(R)-Monepantel has a molecular weight of 473.39 and a molecular formula of C20H13F6N3O2S. Its CAS number is 887148-70-1. The compound is a white solid and should be stored as a powder at -20°C. It is supplied for research purposes only.
|
| Molecular Formula |
C20H13F6N3O2S
|
|---|---|
| Molecular Weight |
473.39
|
| Exact Mass |
473.063
|
| CAS # |
887148-70-1
|
| Related CAS # |
Monepantel;887148-69-8;(Rac)-Monepantel-d5;2747918-33-6;(Rac)-Monepantel sulfone-d5;2747918-68-7
|
| PubChem CID |
11705546
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
32
|
| Complexity |
763
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C[C@](COC1=C(C=CC(=C1)C#N)C(F)(F)F)(C#N)NC(=O)C2=CC=C(C=C2)SC(F)(F)F
|
| InChi Key |
WTERNLDOAPYGJD-GOSISDBHSA-N
|
| InChi Code |
InChI=1S/C20H13F6N3O2S/c1-18(10-28,11-31-16-8-12(9-27)2-7-15(16)19(21,22)23)29-17(30)13-3-5-14(6-4-13)32-20(24,25)26/h2-8H,11H2,1H3,(H,29,30)/t18-/m1/s1
|
| Chemical Name |
N-[(2R)-2-cyano-1-[5-cyano-2-(trifluoromethyl)phenoxy]propan-2-yl]-4-(trifluoromethylsulfanyl)benzamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1124 mL | 10.5621 mL | 21.1242 mL | |
| 5 mM | 0.4225 mL | 2.1124 mL | 4.2248 mL | |
| 10 mM | 0.2112 mL | 1.0562 mL | 2.1124 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
